- A partnership with Medical Kiwi LTD makes it possible for RYAH to enter the New Zealand Market
- Medical Kiwi was the first South Island-based company to be granted a Medicinal Cannabis license from the Ministry of Health to cultivate
- The potential market for medical cannabis in New Zealand is at NZ$1.5 billion
RYAH Group (CSE: RYAH), a health care analytics and technology company, has entered the New Zealand market through a definitive wholesale supply and distribution agreement with Medical Kiwi LTD (https://ibn.fm/jN4T7). This agreement enables RYAH’s suite of IoT devices and cloud-based data analytics to be used in pre-clinical and clinical trial settings and medical patient care alongside Medical Kiwi’s medical cannabis formulations.
“Our new partnership with Medical Kiwi Ltd in New Zealand further expands our global clinical and distribution network for plant-based medicine and digital patient care,” said Gregory Wagner, CEO of RYAH Group Inc. and of RYAH Medtech, Inc.
Medical Kiwi is a leader in research and development, manufacturing, cultivation and distribution of medical cannabis and medical devices in New Zealand. The Company has built a strong health-based, scientific and business savvy team. It offers assurance from seed to sale and has built a reputation on innovation, excellence, quality, transparency and service. It was the first South Island-based Company to be granted a Medicinal Cannabis license from the Ministry of Health to cultivate.
It is difficult for importers of cannabis to enter the New Zealand market, and many who were once there are pulling out, unable to meet stiff new government standards (https://ibn.fm/J0M4I). Medical Kiwi’s medical cannabis formulations are cultivated, produced, and sold domestically. The analytics that RYAH’s IoT and cloud-based data analytics will help provide the necessary information the country desires in its journey to find safer, more effective medicinal products and better understand the medicinal effects.
RYAH is not the cannabis supplier but instead creates partnerships that enable doctors and patients to personalize plant-based treatments to predict treatment outcomes better. The artificial intelligence platform aggregates and correlates HIPAA-compliant patient data throughout the patient session and formulation lifecycle.
The Ministry of Health estimates that over 250,000 casual cannabis users use it for medicinal purposes, with a potential market estimated at NZ$1.5 billion (https://ibn.fm/7cttP).
“Our new relationship with Medical Kiwi presents an opportunity for both parties to drive innovation and to deliver cutting edge plant-based medical solutions in New Zealand,” stated Wagner.
In addition to the partnership, RYAH and Medical Kiwi are looking to explore the medical device registration of RYAH’s Smart-Inhaler, the first of its kind in New Zealand.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php